Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8214930 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 10 Pages |
Abstract
The acute and chronic toxicity profiles associated with these 3 HDR brachytherapy schedules were similar and were well tolerated. Acceptable grade 2, minimal grade 3, and no grade 4 or 5 toxicities were seen. This, combined with the fact that the clinical outcomes were similar, leads to the conclusion that all 3 regimens may be acceptable options for the management of low-risk to intermediate-risk prostate cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Maha Saada MD, Joshua T. MD, PhD, Gary S. MD, Hong MS, Michelle BSN, OCN, Alvaro MD, FACR, Peter Y. MD, FACR, Daniel J. MD,